Enables several functions, including heme binding activity; oxygen binding activity; and tryptophan 2,3-dioxygenase activity. Involved in response to nitroglycerin and tryptophan catabolic process to acetyl-CoA. Human ortholog(s) of this gene implicated in Gilles de la Tourette syndrome and familial hypertryptophanemia. Orthologous to human TDO2 (tryptophan 2,3-dioxygenase); PARTICIPATES IN tryptophan metabolic pathway; kynurenine metabolic pathway; INTERACTS WITH 2,3,7,8-tetrachlorodibenzodioxine; 2,6-di-tert-butyl-4-methylphenol; 3H-1,2-dithiole-3-thione.
[Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of TDO2 mRNA, Tetrachlorodibenzodioxin promotes the reaction [AHR protein binds to TDO2 gene]
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of TDO2 mRNA], [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of TDO2 mRNA
Dexamethasone promotes the reaction [TDO2 enhancer binds to HNRNPU protein], Dexamethasone promotes the reaction [TDO2 promoter binds to HNRNPU protein]
Metformin inhibits the reaction [Dexamethasone results in increased expression of TDO2 mRNA], Metformin inhibits the reaction [Dexamethasone results in increased expression of TDO2 protein]
[Sulindac results in decreased activity of TDO2 protein] which results in decreased abundance of Dopamine, [Tolmetin results in decreased activity of TDO2 protein] which results in decreased abundance of Dopamine
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TDO2 mRNA
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of TDO2 mRNA], [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of TDO2 mRNA
Metformin inhibits the reaction [Dexamethasone results in increased expression of TDO2 mRNA], Metformin inhibits the reaction [Dexamethasone results in increased expression of TDO2 protein]
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TDO2 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TDO2 mRNA
[Sulindac results in decreased activity of TDO2 protein] which results in increased abundance of Serotonin, [Tolmetin results in decreased activity of TDO2 protein] which results in increased abundance of Serotonin
[Sulindac results in decreased activity of TDO2 protein] which results in decreased abundance of Dopamine, [Sulindac results in decreased activity of TDO2 protein] which results in increased abundance of Serotonin
Exon and intron variants in the human tryptophan 2,3-dioxygenase gene: potential association with Tourette syndrome, substance abuse and other disorders.
The role of tryptophan 2,3-dioxygenase in the hormonal control of tryptophan metabolism in isolated rat liver cells. Effects of glucocorticoids and experimental diabetes.
The metabolism of L-tryptophan by isolated rat liver cells. Quantification of the relative importance of, and the effect of nutritional status on, the individual pathways of tryptophan metabolism.
